New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - leflunomide 20mg - tablet - 20 mg - active: leflunomide 20mg excipient: colloidal silicon dioxide crospovidone lactose magnesium stearate - apo-leflunomide is indicated for the treatment of: · rheumatoid arthritis, to improve signs and symptoms to retard joint destruction and to improve functional ability and quality of life. leflunomide may be used in patients who have failed to respond to other treatments or as a first line of treatment in patients who have a contraindication to other treatments. · active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; maize starch; povidone; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; povidone; crospovidone; magnesium stearate; lactose monohydrate; maize starch; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Canada - English - Health Canada

apotex inc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

pharmascience inc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

pharmel inc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

dominion pharmacal - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

mylan pharmaceuticals ulc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

nu-pharm inc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

teva canada limited - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents